82 related articles for article (PubMed ID: 27098617)
1. Immunohistochemical Expression of mTOR in Multiple Myeloma: Retrospective Analysis of 31 Cases, a Clinicopathological Study.
Stockwin W; Johnson P; Vajpayee N
Ann Clin Lab Sci; 2016; 46(2):125-31. PubMed ID: 27098617
[TBL] [Abstract][Full Text] [Related]
2. Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.
Scott EC; Maziarz RT; Spurgeon SE; Medvedova E; Gajewski J; Reasor-Heard S; Park B; Kratz A; Thomas GV; Loriaux M; Cascio M; Podolak J; Gordon M; Botelho J; Stadtmauer E; Amaravadi R; Vogl DT
Haematologica; 2017 Jul; 102(7):e261-e265. PubMed ID: 28385778
[No Abstract] [Full Text] [Related]
3. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
[TBL] [Abstract][Full Text] [Related]
6. SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway.
Han K; Xu X; Xu Z; Chen G; Zeng Y; Zhang Z; Cao B; Kong Y; Tang X; Mao X
Sci Rep; 2015 Sep; 5():12809. PubMed ID: 26329846
[TBL] [Abstract][Full Text] [Related]
7. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
[TBL] [Abstract][Full Text] [Related]
9. The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma.
Li J; Zhu J; Cao B; Mao X
Curr Pharm Des; 2014; 20(1):125-35. PubMed ID: 24001224
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of mTOR in germinal center and nongerminal center group of diffuse large B-cell lymphoma: a clinicopathological study.
Vajpayee N; Burack R; Wang D; Hutchison RE; Gajra A
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):159-63. PubMed ID: 25458080
[TBL] [Abstract][Full Text] [Related]
12. Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma.
Liu Z; Liu H; Li Y; Wang Y; Xing R; Mi F; Xiang C; Fu R
Int J Mol Med; 2020 Apr; 45(4):1112-1120. PubMed ID: 31985020
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.
Righi L; Volante M; Rapa I; Tavaglione V; Inzani F; Pelosi G; Papotti M
Endocr Relat Cancer; 2010 Dec; 17(4):977-87. PubMed ID: 20817788
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
15. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.
Takahashi Y; Kohashi K; Yamada Y; Endo M; Setsu N; Ishii T; Yamamoto H; Iwamoto Y; Oda Y
Hum Pathol; 2014 May; 45(5):984-93. PubMed ID: 24746202
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.
Chuang WY; Chang YS; Chao YK; Yeh CJ; Ueng SH; Chang CY; Liu YH; Tseng CK; Chang HK; Wan YL; Hsueh C
Int J Clin Exp Pathol; 2015; 8(10):12757-65. PubMed ID: 26722465
[TBL] [Abstract][Full Text] [Related]
17. Uniform expression of Notch1, suppressor of B-cell-specific gene expression, in plasmablastic lymphoma.
Seegmiller AC; Wang HY; Hladik C; Chen W
Arch Pathol Lab Med; 2011 Jun; 135(6):770-5. PubMed ID: 21631271
[TBL] [Abstract][Full Text] [Related]
18. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma.
Leal P; García P; Sandoval A; Letelier P; Brebi P; Ili C; Álvarez H; Tapia O; Roa JC
Arch Pathol Lab Med; 2013 Apr; 137(4):552-7. PubMed ID: 23544944
[TBL] [Abstract][Full Text] [Related]
20. Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: a clinicopathological study.
Vajpayee N; Thakral C; Gopaluni S; Newman N; Gajra A
Leuk Res; 2012 Nov; 36(11):1403-9. PubMed ID: 22902049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
